The subject of gene patentability is one of the most controversial topics in life sciences. In June 2013, the US Supreme Court reached a unanimous decision in the Association for Molecular Pathology v Myriad Genetics. It stated that companies cannot patent parts of naturally occurring human genes. Managing IP sat down with Fitzpatrick Cella Harper & Scinto attorneys Robert Fischer, John Carlin and Joshua Rothman to discuss the ruling
Unlock this content.
The content you are trying to view is exclusive to our subscribers.
Partner Ranjini Acharya explains how her Federal Circuit debut resulted in her convincing the court to rule that machine learning technology was not patent-eligible
Rulings of note covered pre-June 2023 infringements and jurisdiction over non-UPC states, while winners of Managing IP’s EMEA Awards acted in multiple cases